Strategic Acquisition CMIC, a biotechnology CRO with GLP-compliant facilities and 30+ years of bioanalytical expertise, recently became part of SGS North America, signaling enhanced global reach and expanded North American bioanalysis capabilities that present cross-selling opportunities to SGS client base in need of bioanalytical and CRO services.

Bioanalysis Focus Strong emphasis on TK, PK, ADA assays for small molecules, oligonucleotides, biologics and biomarkers positions CMIC as a potential partner for pharma and biotech companies pursuing complex bioanalytical programs and scalable GLP/non-GLP testing in early to late-stage development.

AI and Ops Recent collaboration with Bluenote to transform clinical development operations using Agentic AI indicates a strategic push toward AI-enabled workflows, offering a sales angle to companies seeking accelerated data insights, improved trial efficiency, and digital trial optimization.

Global Partnerships Existing alliances with Moffitt Cancer Center and Rutgers highlight CMIC’s capability to support global cancer trials and integrate academic collaborations, suggesting opportunities to approach translational and academic biotech programs seeking CRO partnerships for expansive trial execution.

Financial and Scale Readiness Revenue range of 25-50 million and recent acquisition by SGS imply financial scale, reliability, and expanded capacity for high-volume projects, making CMIC an attractive CRO partner for mid to late-stage programs requiring robust throughput and QA/compliance readiness.